EU
EU6.F PDS Biotechnology Corp
- Market cap
- EUR 121M
- P/E
- -
- P/B
- 3.58x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EU6.F undervalued?
Graham numberThe Graham number of PDS Biotechnology Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PDS Biotechnology Corp fundamental analysis
No fundamental analysis for PDS Biotechnology Corp yet.
PDS Biotechnology Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy util…
Full company profilePDS Biotechnology Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PDS Biotechnology Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -39.5M | -52.0M | -30.4M | -18.1M | -14.9M | -21.4M | -41.7M | -43.0M | -36.3M | -31.5M | -26.0M |
| EBITDA | - | -51.1M | -42.1M | -7.25M | -14.8M | -21.4M | -40.7M | -40.1M | -33.8M | -30.3M | -25.4M |
| Net Income | -38.8M | -50.9M | -40.9M | -7.00M | -14.8M | -16.9M | -40.9M | -42.9M | -37.6M | -34.5M | -34.2M |
| EPS | - | -33 | -26 | -1.33 | -0.67 | -0.59 | -1.35 | -1.30 | -0.99 | -0.63 | -0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 111M | 92.6M | 36.2M | 14.5M | 30.9M | 67.2M | 77.0M | 59.4M | 45.4M | 30.5M | 8.81M |
| Total Liabilities | 21.6M | 30.2M | 6.38M | 2.79M | 3.76M | 3.99M | 33.0M | 33.3M | 26.4M | 21.2M | 12.4M |
| Shareholders' Equity | 89.3M | 62.4M | 29.8M | 11.7M | 27.1M | 63.2M | 44.0M | 26.1M | 19.0M | 9.25M | -3.58M |
| Cash & Short-term Investments | 106M | 88.1M | 34.6M | 12.2M | 28.8M | 65.2M | 73.8M | 56.6M | 41.7M | 26.7M | 5.60M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.76M | -2.73M | -1.57M | -18.1M | -13.1M | -12.5M | -25.7M | -33.6M | -35.0M | -27.8M | -14.3M |
| Capital Expenditure | 687K | 2.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.0K | 0.00 | 0.00 |
| Free Cash Flow | - | -40.9M | -33.2M | -18.1M | -13.1M | -12.5M | -25.7M | -33.6M | -35.1M | -27.8M | -14.3M |
| Ratios | |||||||||||
| ROE | -43.5% | -81.5% | -137.0% | -59.8% | -54.7% | -26.8% | -92.8% | -164.3% | -197.9% | -372.9% | - |
| ROA | -35.0% | -54.9% | -112.8% | -48.3% | -48.1% | -25.2% | -53.1% | -72.3% | -82.9% | -113.1% | -388.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
PDS Biotechnology Corp dividends
PDS Biotechnology Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Mar 18, 2019.
Who owns PDS Biotechnology Corp
- Insiders 19.11%
- Institutions 12.11%
- Public & others 68.78%
- Shares outstanding 123M
- Free float 44.8M
PDS Biotechnology Corp company profile
- Company name
- PDS Biotechnology Corp
- Ticker
- EU6.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 303A College Road East, Princeton, NJ, United States, 08540
- Phone
- 800 208 3343
- Website
- pdsbiotech.com
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corp management
5- Dr. Frank K. Bedu-Addo Ph.D.Founder, President, CEO, Interim CFO & Director · born 1965
- Dr. Kirk V. Shepard M.D.Chief Medical Officer · born 1952
- Ms. Janetta TrochimiukController & Interim Principal Accounting Officer · born 1963
- Dr. Gregory L. Conn Ph.D.Chief Scientific Officer · born 1956
- Mr. Spencer Brown J.D.Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer · born 1970